Document Detail


Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
MedLine Citation:
PMID:  17715246     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The Women's Health Initiative (WHI) randomized trial of estrogen plus progestin (E + P) was terminated early based on an assessment of harms exceeding benefits for disease prevention. The results contravened prevailing wisdom and a large body of literature regarding benefits of menopausal hormone therapy. The results and their interpretation have been the subject of considerable debate. PURPOSE/METHODS: To describe the process of developing a trial monitoring plan, the key interim and final data, and to explain the choice of statistical methods used in trial monitoring and reporting. RESULTS: A formalized monitoring plan was developed using statistical methods that acknowledged protocol-defined design and analysis plans, input of monitoring board members especially regarding the role of various study outcomes, and multiple comparisons. Major early departures from design assumptions concerning treatment effects indicated a need for additional flexibility in safety monitoring. When the trials were stopped early, questions arose as to how closely the statistical methods in published reports should correspond to those defined by protocol or used in monitoring. METHODS: were selected to provide a simple and transparent summary of the primary results, with a cautious interpretation promoted by acknowledgement of multiple testing. CONCLUSIONS: Developing a formal trial monitoring plan with a view towards influencing clinical practice is useful for creating consensus among DSMB members regarding the evidence that would justify stopping a trial and the framework to be used to address statistical complexities. Departures from design assumptions typically occur. These reinforce the role of the DSMB in exercising their judgment, and the judicious adaptation of these statistical guidelines in monitoring and reporting trials. In communicating the results in such circumstances, priority should be given to presenting as fair, accurate and transparent a view of the data and findings as current methods and technology allow.
Authors:
Garnet L Anderson; Charles Kooperberg; Nancy Geller; Jacques E Rossouw; Mary Pettinger; Ross L Prentice
Related Documents :
10264176 - Grant application cycles; health systems agency grants and state health planning and de...
1738806 - The role of data-driven planning and coalition development in preventing cardiovascular...
20845196 - The development of a health literacy assessment tool for health plans.
25429306 - Managing evaluation: a community arts organisation perspective.
8108396 - Social factors and health: the causation-selection issue revisited.
9334496 - The soft-tissue components of the vomeronasal organ in pigs, cows and horses.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Clinical trials (London, England)     Volume:  4     ISSN:  1740-7745     ISO Abbreviation:  Clin Trials     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-23     Completed Date:  2007-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197451     Medline TA:  Clin Trials     Country:  England    
Other Details:
Languages:  eng     Pagination:  207-17     Citation Subset:  IM    
Affiliation:
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. garnet@whi.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials Data Monitoring Committees / organization & administration*
Data Interpretation, Statistical
Estrogen Replacement Therapy*
Estrogens / therapeutic use
Female
Humans
Progesterone Congeners / therapeutic use
Randomized Controlled Trials as Topic / methods*,  statistics & numerical data*
Research Design
Risk Assessment
Women's Health*
Grant Support
ID/Acronym/Agency:
CA53996/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Estrogens; 0/Progesterone Congeners
Comments/Corrections
Comment In:
Clin Trials. 2007;4(3):205-6   [PMID:  17715245 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract i...
Next Document:  Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Sa...